Company intelligence / Profile preview

Tangtang Quan

Ownership: Private
Development stage: Commercial

Overview

Tangtang Quan has developed a digital therapeutic solution that integrates an artificial pancreas with real-time blood sugar monitoring, delivered via a smartwatch-based platform. The technology aims to simplify diabetes management, particularly for children and disadvantaged populations. Clinical results are not detailed in public sources, but the product is described as transformative in improving ease-of-use for patients managing type 1 diabetes[1].

Therapeutic areas: Endocrinology
Modalities: DeviceDigital therapeuticArtificial pancreas systemBlood glucose monitoring system
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed. Participated in OPPO Research Institute Innovation Accelerator program[1].

Beyond the preview

Go deeper on Tangtang Quan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tangtang Quan.

Explore the full profile